June 13, 2018 – EOS imaging announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its hipEOS 3.0 surgical planning software.
hipEOS 3.0 is the latest generation of the surgical planning software for total hip arthroplasty (THA) and is part of the EOSapps suite of online 3-D surgical planning solutions (spineEOS, hipEOS, kneeEOS). The EOSapps — based on unbiased, weight-bearing EOS images and an accurate 2-D/3-D patient-specific data set — automatically select and best-position implants in 3-D. This enables surgeons to identify patient risks and develop customized plans based on each patient’s unique 3-D anatomy. Specifically, hipEOS 3.0 simulates the patient’s hip range of motion based on EOS functional standing and seated exams, allowing physicians to visualize and anticipate impingement and dislocation risks based on the position of the implant components.
When the hipEOS solution is utilized, the software offers an initial plan for the size and position of the implant components based on the patient’s 3-D data and anatomical model. The plan can be further adjusted by the physician with immediate feedback on how changes affect relevant clinical parameters. With the patient-specific data from full body, weight-bearing 2-D/3-D EOS images, hipEOS can be used to anticipate and better plan for the outcome of the surgical strategy, including leg length discrepancies, femoral offset and torsion, as well as hip mobility.
For more information: www.eos-imaging.com